Overview of the Recent Transaction On September 30, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, significantly increased its investment in Exact Sciences Corp (EXAS, Financial), a leader in cancer diagnostics. The firm acquired an additional 8,418,428 shares at a price of $68.12 each, elevating its total holdings to 22,042,464 shares. This strategic move not only reflects FMR LLC (Trades, Portfolio)'s confidence in Exact Sciences but also marks a notable adjustment in its portfolio, with ...

Exact Sciences Corporation (EXAS) is making robust efforts to further promote Cologuard as the standard of care, building on its established reputation. The company’s progress across its pipeline is highly encouraging, with several new solutions expected to debut in the market in the coming months. On top of this, its sound financial health bodes well. Yet, cost pressures from macroeconomic challenges and excessive reliance on its lead brand raise concerns for Exact Sciences.Meanwhile, surging costs from ma ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying EXAS stock? Here’s what analysts think: Read Next: ...

Exact Sciences (EXAS) closed the last trading session at $59.11, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $79.40 indicates a 34.3% upside potential.The average comprises 20 short-term price targets ranging from a low of $61 to a high of $100, with a standard deviation of $9.54. While the lowest estimate indicates an increase of 3.2% from the current price level, ...

Exact Sciences Corporation (NASDAQ:EXAS) Wells Fargo 2024 Healthcare Conference September 5, 2024 3:45 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Brandon Couillard Alright, folks. We'll go ahead and get started. Good afternoon. Welcome to the Wells Fargo Healthcare Conference. I'm Brandon Couillard, cover the life science tools and diagnostics sector here at the firm now. And it's my great pleasure to have Exact Sciences wi ...

It has been about a month since the last earnings report for Exact Sciences (EXAS) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Exact Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Exact Sciences Reports Narrower-Than-Expe ...

Exact Sciences (EXAS) closed the last trading session at $59.68, gaining 24.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $80.05 indicates a 34.1% upside potential.The average comprises 19 short-term price targets ranging from a low of $61 to a high of $100, with a standard deviation of $9.70. While the lowest estimate indicates an increase of 2.2% from the current price level ...

Exact Sciences (EXAS) continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising. The stock carries a Zacks Rank #2 (Buy) currently.Exact Sciences is focusing on three areas to enhance its flagship Cologuard’s growth. The first is to build the best and most effective commercial organization in healthcare by investing in the leadership team, training, and sales force effectiveness. Second, it intend ...

Exact Sciences Corporation (EXAS) recently enrolled the first patient in its pivotal Multi-Cancer Early Detection (“MCED”) Falcon Registry Real-World Evidence (“RWE”) study. The Texas-based not-for-profit health system, Baylor Scott & White, will serve as the principal site for the study, with Endeavor Health in Chicago set to begin enrolling patients this fall.The multi-site study will register up to 25,000 patients, evaluating the clinical performance, patient and provider experience, and psychological im ...

Hiroshi Watanabe Since I last covered Exact Sciences (NASDAQ:NASDAQ:EXAS) back in August 2021 it is down by around 35%, it is trading at around $58.75 as per the chart below. This thesis aims to show that the recent upside should continue amid volatility. Data by YCharts Three years back, I had a hold position as despite the biotech's DNA-based cancer diagnostics products becoming mainstream, this field involved heavy R&D expenses with competition faced from the likes of Invitae (OTCPK:OTC:NVTAQ). It wa ...